BioCentury
ARTICLE | Company News

Orion, Mylan, Novartis neurology news

December 24, 2012 8:00 AM UTC

The companies settled a January 2011 suit filed in the U.S. District Court for the District of Delaware claiming Mylan's ANDA for a generic version of Parkinson's drug (PD) Comtan entacapone infringes Orion's U.S. Patent No. 5,446,194. The patent covers pharmacologically active catechol derivatives and expires on Oct. 19, 2013. Under the settlement, Mylan may begin marketing its generic version of 200 mg Comtan on April 1, 2013, at the earliest. Mylan submitted the ANDA in 2010 (see BioCentury, Jan. 31, 2011). ...